Benchmark Reiterates Speculative Buy on Alterity Therapeutics, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman reiterates a Speculative Buy rating on Alterity Therapeutics (NASDAQ:ATHE) and maintains a $4 price target.
March 07, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Benchmark analyst Robert Wasserman reiterates a Speculative Buy rating on Alterity Therapeutics and maintains a $4 price target.
The reiteration of a Speculative Buy rating and the maintenance of a $4 price target by a Benchmark analyst could positively influence investor sentiment towards ATHE, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100